Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Abbott Laboratories (ABT - Analyst Report) received positive news when the U.S. Food and Drug Administration (FDA) approved its percutaneous valve repair system, MitraClip.

The FDA approved MitraClip device to treat patients with significant symptomatic degenerative mitral regurgitation (MR) who are at prohibitive risk of mitral valve surgery. Consequently, Abbott Labs will launch its MitraClip device immediately in the U.S.

We note that MitraClip is already approved in the Europe and parts of Asia and Latin America.

Meanwhile, Abbott Labs continues to evaluate the impact of MitraClip treatment on the progression of heart failure through two randomized trials - COAPT in the U.S. and RESHAPE-HF in Europe.

We note that the vascular business is an important part of Abbott Labs’ product portfolio. The vascular business generated total sales of $2.2 billion in the first nine months of 2013, down 3.1% year over year.

For the third quarter, vascular sales were up 2.5% on an operational basis driven by continued share gains in international markets. Of the total vascular sales, approximately $384 million came from the sale of drug-eluting stents and the bioresorbable vascular scaffold (BVS) product portfolio.

The approval of MitraClip will strengthen Abbott Labs’ vascular business which already has drug-eluting stent, Xience Xpedition and BVS Absorb, under its portfolio.

Moreover, the acquisition of privately-held IDEV Technologies has added SUPERA Veritas stent system to Abbott Labs’ product portfolio.

The stent system is approved in Europe for treating blockages in blood vessels due to peripheral artery disease (PAD). Moreover, SUPERA Veritas is approved in the U.S. for the treatment of biliary strictures (narrowing of a bile duct) related to cancer.

Abbott Labs expects to increase sales in low single digits (excluding foreign exchange rates) in the fourth quarter of 2013.

We believe the launch of new products will help Abbott Labs to broaden its vascular business.

We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc. (ABBV - Analyst Report), in Jan 2013.

Abbott Labs currently carries a Zacks Rank #3 (Hold). Right now, large cap pharma stocks like Bayer (BAYRY - Analyst Report) and Johnson & Johnson (JNJ - Analyst Report) look attractive, each with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%